NCT07467330 2026-03-12
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
Fujian Cancer Hospital
Phase 3 Recruiting
Clinical Trials
18 trialsNCT06301438 2026-02-03
Dalpiciclib in HR+/HER2- ABC
RenJi Hospital
Recruiting
NCT06970912 2026-01-21
DNADalHR
Peking University People's Hospital
Phase 2 Recruiting
NCT07207070 2025-12-30
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 3 Recruiting
NCT07285382 2025-12-16
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT06107673 2025-12-11
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05578053 2025-09-11
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
Hebei Medical University Fourth Hospital
Recruiting
NCT06684600 2024-11-12
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06109207 2024-07-23
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
NCT06149130 2024-04-15
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
Tongji Hospital
Phase 2 Recruiting
NCT06341894 2024-04-02
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06225921 2024-03-06
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
NCT05949541 2024-02-08
BCTOP-L-M01
Fudan University
Phase 2 Recruiting
NCT05759546 2024-02-06
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05759572 2024-02-06
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05638594 2023-03-20
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Shengjing Hospital
Phase 2 Recruiting
NCT05228951 2022-09-13
Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
Shengjing Hospital
Phase 2 Recruiting